시장보고서
상품코드
1485003

NGS 기반 RNA 시퀀싱 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 제품 및 서비스별, 기술별, 용도별, 최종 사용자별, 지역별, 경쟁사별(2019-2029년)

NGS-Based RNA-Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Services, By Technology, By Application, By End User, By Region, and By Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 NGS 기반 RNA 시퀀싱 시장은 2023년 26억 7,000만 달러로 평가되었고, 2029년까지 연평균 6.13% 성장하여 2029년까지 연평균 6.13%의 괄목할 만한 성장을 보일 것으로 예상됩니다.

차세대 시퀀싱(NGS) 기반 RNA 시퀀싱(종종 RNA-Seq로 약칭)은 전사체 분석에 사용되는 강력한 기술로, 연구자들은 RNA-Seq를 통해 유전자 발현 수준, 대체 스플라이싱 패턴, RNA 변형 및 기타 전사체 특성을 높은 처리량과 해상도로 조사할 수 있습니다. 전사체의 특징을 높은 처리량과 분해능으로 조사할 수 있습니다. 원하는 RNA 분자는 RNA의 무결성을 유지하고 분해를 최소화하는 특수 프로토콜을 사용하여 세포 또는 조직에서 추출됩니다. 메신저 RNA(mRNA), 비암호화 RNA(마이크로 RNA, 긴 비암호화 RNA 등), 리보솜 RNA(rRNA)를 포함한 전체 RNA가 샘플에서 분리되고 정제됩니다. 분리된 RNA 분자는 일련의 효소 반응을 통해 시퀀싱 라이브러리로 변환됩니다. 라이브러리 준비 과정에서 RNA는 단편화되고 역전사 효소를 사용하여 상보적 DNA(cDNA)로 역전사되고, 어댑터가 cDNA 단편에 결합되어 염기서열 분석을 가능하게 합니다. 다양한 라이브러리 준비 키트와 프로토콜을 사용하여 사슬 RNA-Seq, poly(A)-enriched RNA-Seq, total RNA-Seq 등 다양한 RNA-Seq 용도에 대응할 수 있습니다. 준비된 RNA-Seq 라이브러리는 Illumina, Ion Torrent, PacBio 시퀀서 등 고처리량 NGS 플랫폼으로 시퀀싱됩니다. 시퀀싱 과정에서 형광 표지된 뉴클레오티드는 DNA 또는 RNA 분자의 상보적 사슬에 통합되어 수백만에서 수십억 개의 짧은 시퀀싱 리드가 초병렬로 생성됩니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 26억 7,000만 달러
시장 규모 : 2029년 38억 2,000만 달러
CAGR : 2024-2029년 6.13%
급성장 부문 나노포아 시퀀싱
최대 시장 북미

차세대 시퀀싱(NGS) 기술의 지속적인 발전으로 RNA 시퀀싱의 속도, 정확성 및 비용 효율성이 크게 향상되었습니다. 롱 리드 시퀀싱, 단일 세포 RNA 시퀀싱, 실시간 시퀀싱 기능 등의 혁신은 RNA 시퀀싱의 응용 범위와 접근성을 확대하여 시장 성장을 주도하고 있습니다. 유전체 연구, 특히 전사체학 및 기능유전체학 등의 분야에 대한 관심과 투자가 증가하면서 RNA 시퀀싱 기술에 대한 수요가 증가하고 있습니다. 분자생물학, 의학, 농업, 생명공학 등 다양한 분야의 연구자들이 유전자 발현, 접합 변이체, RNA 변형, 조절 네트워크를 조사하기 위해 RNA 시퀀싱을 활용하고 있으며, 특히 종양학 및 희귀질환의 임상 진단에 RNA 시퀀싱이 점점 더 많이 활용되고 있습니다. RNA 시퀀싱을 사용하여 유전자 융합, 돌연변이, 발현 패턴을 검출하는 능력은 암의 진단, 예후 및 치료법 선택에 도움이 됩니다. 또한, RNA 시퀀싱은 희귀질환 및 미진단 질환의 원인 유전자 돌연변이 식별을 용이하게 하고, 임상 진료 및 분자 병리학에의 통합을 촉진합니다.

주요 시장 성장 촉진요인

시퀀싱 기술의 발전

유전체 연구의 급격한 성장

임상 진단 분야에서의 응용 확대

주요 시장 과제

데이터 분석 및 해석의 복잡성

샘플의 불균일성 및 복잡성

주요 시장 동향

트랜스크립틱스에 NGS 도입 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별(RNA 시퀀싱 플랫폼 및 소모품, 샘플 조제 제품, RNA 시퀀싱 서비스, 데이터 분석, 보관 및 관리)
    • 기술별(합성에 의한 시퀀싱, 이온 반도체 시퀀싱, 단일 분자 실시간 시퀀싱, 나노포어 시퀀싱)
    • 용도별(발현 프로파일링 분석, 소규모 RNA 시퀀싱, 디노보 전사체 어셈블리, 변이체 호출 및 전사체 후성유전학))
    • 최종사용자별(연구 및 학술기관, 병원 및 진료소, 제약 기업 및 바이오테크놀러지 기업, 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵

제6장 북미의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가별 분석
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인

제8장 아시아태평양의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 남미의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 NGS 기반 RNA 시퀀싱 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 및 서비스별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 합병 및 인수(해당하는 경우)
  • 제품 발매(있는 경우)
  • 최근 동향

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Illumina Inc.
  • Thermo Fischer Scientific Inc.
  • Oxford Nanopore Technologies plc
  • Agilent Technologies, Inc.
  • PerkinElmer Inc
  • QIAGEN N.V
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Takara Bio Inc.
  • Azenta Life Sciences

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.03

Global NGS-Based RNA-Sequencing Market was valued at USD 2.67 billion in 2023 and will see an impressive growth in the forecast period at a CAGR of 6.13% through 2029. Next-Generation Sequencing (NGS)-Based RNA-Sequencing, often abbreviated as RNA-Seq, is a powerful technique used to analyze the transcriptome, which refers to the complete set of RNA molecules in a cell or tissue at a specific time point. RNA-Seq allows researchers to investigate gene expression levels, alternative splicing patterns, RNA modifications, and other transcriptomic features with high throughput and resolution. The RNA molecules of interest are extracted from cells or tissues using specialized protocols that preserve RNA integrity and minimize degradation. Total RNA, which includes messenger RNA (mRNA), non-coding RNA (e.g., microRNA, long non-coding RNA), and ribosomal RNA (rRNA), is isolated and purified from the sample. The isolated RNA molecules are converted into a sequencing library through a series of enzymatic reactions. During library preparation, the RNA is fragmented into smaller pieces, reverse transcribed into complementary DNA (cDNA) using reverse transcriptase enzymes, and adapters are ligated to the cDNA fragments to enable sequencing. Various library preparation kits and protocols are available to accommodate different RNA-Seq applications, such as stranded RNA-Seq, poly(A)-enriched RNA-Seq, and total RNA-Seq. The prepared RNA-Seq libraries are sequenced using high-throughput NGS platforms, such as Illumina, Ion Torrent, or PacBio sequencers. During sequencing, fluorescently labeled nucleotides are incorporated into complementary strands of DNA or RNA molecules, generating millions to billions of short sequencings reads in a massively parallel fashion.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 2.67 Billion
Market Size 2029USD 3.82 Billion
CAGR 2024-20296.13%
Fastest Growing SegmentNanopore Sequencing
Largest MarketNorth America

Continuous advancements in next-generation sequencing (NGS) technologies have significantly improved the speed, accuracy, and cost-effectiveness of RNA sequencing. Innovations such as long-read sequencing, single-cell RNA sequencing, and real-time sequencing capabilities have expanded the applications and accessibility of RNA sequencing, driving market growth. The growing interest and investment in genomic research, particularly in areas such as transcriptomics and functional genomics, fuel the demand for RNA sequencing technologies. Researchers across various fields, including molecular biology, medicine, agriculture, and biotechnology, rely on RNA sequencing to investigate gene expression, splicing variants, RNA modifications, and regulatory networks. RNA sequencing is increasingly utilized for clinical diagnostics, particularly in oncology and rare diseases. The ability to detect gene fusions, mutations, and expression patterns using RNA sequencing aids in cancer diagnosis, prognosis, and treatment selection. Additionally, RNA sequencing facilitates the identification of causative genetic variants in rare and undiagnosed diseases, driving its integration into clinical practice and molecular pathology.

Key Market Drivers

Advancements in Sequencing Technologies

NGS technologies represent a paradigm shift in DNA sequencing, allowing for high-throughput sequencing of DNA and RNA molecules. NGS platforms, such as Illumina's sequencing systems, enable researchers to sequence millions of DNA fragments or RNA transcripts in parallel, significantly increasing sequencing speed and throughput compared to traditional Sanger sequencing methods. Single-cell sequencing technologies enable the profiling of individual cells' genomes, transcriptomes, and epigenomes with high resolution. These technologies, including single-cell RNA sequencing (scRNA-seq), single-cell DNA sequencing (scDNA-seq), and single-cell ATAC-seq (scATAC-seq), provide insights into cellular heterogeneity, developmental processes, and disease mechanisms at the single-cell level. Long-read sequencing technologies, such as those offered by Pacific Biosciences (PacBio) and Oxford Nanopore Technologies, generate sequencing reads that span thousands to tens of thousands of base pairs. Long-read sequencing facilitates the detection of structural variations, complex genomic rearrangements, and full-length transcripts, overcoming limitations associated with short-read sequencing technologies.

Real-time sequencing platforms, such as nanopore sequencing by Oxford Nanopore Technologies, enable the direct, label-free detection of nucleic acids as they pass through nanopores. Real-time sequencing provides rapid turnaround times, enables dynamic monitoring of biological processes, and supports applications such as pathogen detection, environmental surveillance, and RNA transcript analysis. Epigenetic sequencing technologies, including DNA methylation sequencing (e.g., bisulfite sequencing) and chromatin immunoprecipitation sequencing (ChIP-seq), allow researchers to study epigenetic modifications and chromatin dynamics at genome-wide scales. These technologies provide insights into gene regulation, cell differentiation, and disease mechanisms by profiling DNA methylation patterns, histone modifications, and transcription factor binding sites. Metagenomic sequencing enables the comprehensive analysis of microbial communities and environmental samples without the need for culture-based methods. Metagenomic sequencing technologies, such as shotgun metagenomics and 16S rRNA gene sequencing, facilitate the identification of microbial species, functional gene annotation, and microbiome characterization in diverse habitats, including the human gut, soil, water, and air. This factor will help in the development of the Global NGS-Based RNA-Sequencing Market.

Rapid Growth of Genomic Research

Genomic research encompasses a wide range of applications, including transcriptomics, epigenomics, metagenomics, and comparative genomics. RNA sequencing, specifically, provides insights into gene expression patterns, alternative splicing events, RNA modifications, and regulatory networks. Researchers leverage RNA sequencing data to study development, disease mechanisms, drug responses, and evolutionary relationships across diverse biological systems. Advances in NGS technologies have democratized genomic research by enabling high-throughput sequencing of DNA and RNA molecules at unprecedented speed and scale. NGS platforms, such as Illumina's sequencing systems and those offered by other manufacturers, facilitate the generation of large volumes of sequencing data with high accuracy and resolution. These technological advancements have expanded the accessibility of RNA sequencing to researchers in academia, industry, and clinical settings. The decreasing costs of sequencing technologies and associated reagents have made RNA sequencing more affordable and accessible to research laboratories worldwide. As the price per base pair continues to decline, researchers can conduct large-scale RNA sequencing experiments, population-based studies, and longitudinal analyses without significant financial constraints. The affordability of RNA sequencing drives its widespread adoption across diverse research disciplines and institutions.

Genomic research increasingly integrates RNA sequencing with other omics technologies, such as DNA sequencing, epigenetic profiling, proteomics, and metabolomics. Multi-omics approaches enable comprehensive molecular profiling and systems-level analysis of biological systems, providing a holistic view of gene regulation, signaling pathways, and cellular interactions. RNA sequencing data complement other omics datasets, enhancing our understanding of complex biological processes and disease phenotypes. Genomic research findings have translational implications for healthcare, agriculture, environmental science, and biotechnology. RNA sequencing technologies play a crucial role in translational research and clinical applications, including biomarker discovery, diagnostic assay development, patient stratification, and treatment optimization. RNA sequencing data informs precision medicine approaches, facilitates the identification of therapeutic targets, and support evidence-based decision-making in clinical practice. This factor will pace up the demand of the Global NGS-Based RNA-Sequencing Market.

Expanding Applications in Clinical Diagnostics

NGS-based RNA sequencing enables precise molecular characterization of diseases, aiding in the development of personalized treatment strategies. By profiling RNA expression patterns, identifying genetic mutations, and detecting fusion genes, RNA sequencing helps clinicians tailor therapies to individual patients based on their unique genetic profiles. RNA sequencing is instrumental in cancer diagnostics and prognostics. It allows for the identification of gene expression signatures associated with different cancer types, tumor subtypes, and disease progression stages. RNA sequencing can detect driver mutations, predict treatment responses, monitor minimal residual disease, and identify drug resistance mechanisms, guiding clinical decision-making in oncology. NGS-based RNA sequencing facilitates the diagnosis of rare and undiagnosed diseases by identifying causative genetic variants, including point mutations, insertions/deletions, and copy number variations. RNA sequencing can uncover pathogenic mutations affecting gene expression, splicing, and regulatory elements, providing insights into disease mechanisms, and informing genetic counseling and family planning. RNA sequencing is increasingly used in the diagnosis and surveillance of infectious diseases, including viral infections, bacterial pathogens, and fungal pathogens. RNA sequencing can detect microbial RNA transcripts, viral RNA genomes, and host immune responses, enabling the rapid identification and characterization of infectious agents, monitoring of disease outbreaks, and assessment of antimicrobial resistance patterns.

RNA sequencing plays a crucial role in pharmacogenomics by identifying genetic variants associated with drug metabolism, drug efficacy, and adverse drug reactions. RNA sequencing data can predict individual responses to pharmacotherapy, optimize drug dosing regimens, and minimize adverse drug events, enhancing patient safety and treatment outcomes in clinical practice. RNA sequencing is utilized in non-invasive prenatal testing to detect fetal chromosomal abnormalities, such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). RNA sequencing of cell-free fetal RNA in maternal blood enables early detection of genetic disorders, reducing the need for invasive procedures like amniocentesis and chorionic villus sampling. RNA sequencing enables the analysis of circulating RNA biomarkers in blood, urine, and other body fluids for cancer detection, monitoring treatment response, and assessing disease recurrence. Liquid biopsy-based RNA sequencing offers a minimally invasive alternative to tissue biopsies and facilitates real-time monitoring of disease dynamics and therapeutic interventions. This factor will accelerate the demand of the Global NGS-Based RNA-Sequencing Market.

Key Market Challenges

Data Analysis and Interpretation Complexity

RNA-sequencing generates massive amounts of raw sequencing data that require sophisticated bioinformatics tools and computational expertise for analysis and interpretation. Analyzing transcriptomic data involves multiple steps, including quality control, read alignment, transcript quantification, differential gene expression analysis, pathway analysis, and functional annotation. Researchers often need specialized training in bioinformatics and computational biology to effectively analyze RNA-sequencing data and extract meaningful biological insights. There is a lack of standardized data analysis pipelines for RNA-sequencing data, leading to variability in analysis methodologies and results across different studies and laboratories. Researchers may use different software tools, algorithms, and parameters for data processing and analysis, which can impact the reproducibility and comparability of results. Establishing consensus guidelines and best practices for RNA-sequencing data analysis is essential for promoting consistency and transparency in research findings. RNA-sequencing data are inherently complex, reflecting the dynamic nature of gene expression and alternative splicing events across different biological conditions and cell types. Analyzing transcriptomic data requires accounting for various sources of variability, including technical noise, biological heterogeneity, and experimental confounders. Moreover, identifying biologically relevant signals amidst background noise and false positives poses challenges for data interpretation and validation.

Integrating RNA-sequencing data with other omics data types, such as genomics, proteomics, and metabolomics, adds another layer of complexity to data analysis and interpretation. Integrated multi-omics analyses enable researchers to gain a more comprehensive understanding of biological systems and disease mechanisms. However, integrating heterogeneous data sets from different experimental platforms and data sources requires specialized computational methods and tools for data integration, normalization, and statistical analysis. Ensuring the reproducibility and reliability of RNA-sequencing results is a critical concern in the field. Researchers must implement rigorous quality control measures throughout the experimental workflow to minimize technical artifacts, batch effects, and systematic biases that can confound data analysis and interpretation. Standardizing quality control metrics and reporting guidelines for RNA-sequencing experiments can help improve data reproducibility and facilitate data sharing and meta-analysis efforts.

Sample Heterogeneity and Complexity

Biological samples, particularly tissues and organs, consist of diverse cell populations with distinct gene expression profiles. Studying heterogeneous samples using RNA-sequencing requires methods to capture and analyze gene expression patterns at the single-cell or subpopulation level. Bulk RNA-sequencing may mask cell-specific gene expression signatures, leading to a loss of resolution and biological insights. Tumors are characterized by intratumoral heterogeneity, where different regions of the tumor exhibit distinct molecular profiles and cellular phenotypes. RNA-sequencing studies of tumors must account for spatial and temporal variations in gene expression, as well as the presence of rare cell populations, tumor subclones, and microenvironmental factors. Understanding tumor heterogeneity is critical for identifying therapeutic targets, predicting treatment response, and monitoring disease progression.

Biological systems exhibit dynamic changes in gene expression over time in response to developmental cues, environmental stimuli, and disease processes. Temporal dynamics pose challenges for RNA-sequencing experiments, as gene expression patterns may vary across different time points or experimental conditions. Longitudinal studies and time-series analyses are necessary to capture temporal changes in gene expression and unravel regulatory networks underlying dynamic biological processes. Biological samples are influenced by environmental factors, experimental conditions, and technical artifacts that can introduce variability and confound RNA-sequencing results. Sources of variation include sample processing methods, RNA extraction protocols, library preparation techniques, sequencing platforms, and computational pipelines. Controlling environmental and experimental factors is essential for minimizing batch effects, systematic biases, and false positives in RNA-sequencing experiments. Biological samples may contain rare cell populations or subtypes with unique gene expression profiles that are challenging to detect using bulk RNA-sequencing approaches. Single-cell RNA-sequencing (scRNA-seq) technologies enable the profiling of individual cells within heterogeneous populations, allowing researchers to identify rare cell types, characterize cell-to-cell variability, and dissect cellular heterogeneity at high resolution.

Key Market Trends

Increasing Adoption of NGS in Transcriptomics

NGS-based RNA-sequencing enables researchers to study gene expression patterns across the entire transcriptome in a high-throughput and unbiased manner. Unlike microarray-based methods, which are limited to the detection of predefined probes, RNA-sequencing provides greater sensitivity and dynamic range for detecting transcripts, alternative splicing events, and novel RNA isoforms. The transcriptome is highly complex, consisting of coding and non-coding RNAs with diverse functions and regulatory roles. NGS-based RNA-sequencing allows researchers to profile gene expression at single-nucleotide resolution, identify splice variants, quantify transcript abundance, and characterize RNA modifications with high precision. This resolution enables the discovery of novel transcripts, regulatory elements, and disease-associated biomarkers. NGS-based RNA-sequencing is widely used across various research areas, including basic biology, developmental biology, cancer biology, neuroscience, immunology, and infectious diseases. Transcriptomic studies provide insights into gene regulatory networks, cellular differentiation, disease mechanisms, drug responses, and biomarker discovery, driving the adoption of RNA-sequencing technologies in diverse scientific disciplines.

NGS-based RNA-sequencing is often integrated with other omics data types, such as genomics, epigenomics, proteomics, and metabolomics, to obtain a comprehensive understanding of biological systems and disease processes. Integrated multi-omics approaches enable researchers to correlate gene expression patterns with genetic variations, epigenetic modifications, protein abundance, and metabolic pathways, facilitating systems-level analyses and translational research applications. NGS-based RNA-sequencing is increasingly used in clinical research and diagnostics, particularly in the field of precision medicine. Transcriptomic profiling of patient samples enables the identification of disease-specific gene expression signatures, patient stratification based on molecular subtypes, and prediction of treatment responses. RNA-sequencing data also informs the development of targeted therapies, biomarker-driven clinical trials, and personalized treatment strategies for cancer and other complex diseases.

Segmental Insights

Technology Insights

The Nanopore Sequencing segment is projected to experience rapid growth in the Global NGS-Based RNA-Sequencing Market during the forecast period. Nanopore sequencing technology offers the advantage of producing long read lengths, which enables the direct sequencing of RNA molecules without the need for fragmentation or amplification. Long-read RNA sequencing allows for the characterization of full-length transcripts, including isoforms and splice variants, providing valuable insights into RNA structure, function, and regulation. Researchers and clinicians increasingly recognize the importance of long-read sequencing in accurately capturing complex RNA landscapes, driving the demand for nanopore sequencing platforms. One of the distinctive features of nanopore sequencing is its ability to perform real-time, single-molecule sequencing. This real-time capability allows researchers to observe RNA molecules as they pass through nanopores, enabling dynamic monitoring of RNA modifications, kinetics of RNA processing events, and RNA-protein interactions. Real-time nanopore sequencing offers unprecedented insights into RNA biology and gene expression dynamics, making it an attractive tool for a wide range of research applications. Nanopore sequencing platforms, such as those offered by Oxford Nanopore Technologies, are known for their portability and ease of use. These compact, handheld devices enable RNA sequencing to be performed in various settings, including fieldwork, point-of-care diagnostics, and resource-limited environments. The accessibility and flexibility of nanopore sequencing systems democratize RNA sequencing and empower researchers and clinicians worldwide to conduct studies and diagnostics in diverse settings. Nanopore sequencing is versatile and applicable to a wide range of RNA sequencing applications, including transcriptome profiling, RNA modification analysis, RNA structural characterization, and viral RNA detection. The versatility of nanopore sequencing technology allows researchers to address diverse research questions and explore RNA biology in unprecedented detail, fostering its widespread adoption across academic, clinical, and industrial settings.

Regional Insights

North America emerged as the dominant region in the Global NGS-Based RNA-Sequencing Market in 2023. North America, particularly the United States, is a leading hub for biomedical research and innovation. The region is home to numerous prestigious universities, research institutions, and biotechnology companies that actively invest in genomics and RNA sequencing technologies. This concentration of expertise and resources fosters the development and adoption of next-generation sequencing (NGS) techniques, including RNA sequencing. North America boasts a robust biotechnology and pharmaceutical industry, comprising both established companies and startups. These organizations conduct extensive research and development (R&D) in areas such as drug discovery, diagnostics, and personalized medicine, all of which heavily rely on RNA sequencing technologies. The demand for NGS-based RNA sequencing solutions is driven by the need to understand gene expression patterns, identify therapeutic targets, and develop novel treatments for diseases.

Key Market Players

Illumina Inc.

Thermo Fischer Scientific Inc.

Oxford Nanopore Technologies plc

Agilent Technologies, Inc.

PerkinElmer Inc

QIAGEN N.V.

Eurofins Scientific SE

F. Hoffmann-La Roche Ltd

Takara Bio Inc.

Azenta Life Sciences

Report Scope:

In this report, the Global NGS-Based RNA-Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

NGS-Based RNA-Sequencing Market, By Product and Services:

    RNA Sequencing Platforms and Consumables Sample Preparation Products RNA Sequencing Services Data Analysis Storage and Management

NGS-Based RNA-Sequencing Market, By Technology:

    Sequencing by Synthesis Ion Semiconductor Sequencing Single-Molecule Real-Time Sequencing Nanopore Sequencing

NGS-Based RNA-Sequencing Market, By Application:

    Expression Profiling Analysis Small RNA Sequencing De Novo Transcriptome Assembly Variant Calling and Transcriptome Epigenetics

NGS-Based RNA-Sequencing Market, By End User:

    Research and Academia Hospitals and Clinics Pharmaceutical and Biotechnology Companies Others

NGS-Based RNA-Sequencing Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global NGS-Based RNA-Sequencing Market.

Available Customizations:

Global NGS-Based RNA-Sequencing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global NGS-Based RNA-Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product and Services (RNA Sequencing Platforms and Consumables, Sample Preparation Products, RNA Sequencing Services, Data Analysis, Storage and Management)
    • 5.2.2. By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing)
    • 5.2.3. By Application (Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics)
    • 5.2.4. By End User (Research and Academia, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America NGS-Based RNA-Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product and Services
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States NGS-Based RNA-Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product and Services
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada NGS-Based RNA-Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product and Services
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico NGS-Based RNA-Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product and Services
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe NGS-Based RNA-Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product and Services
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany NGS-Based RNA-Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product and Services
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom NGS-Based RNA-Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product and Services
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy NGS-Based RNA-Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product and Services
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. France NGS-Based RNA-Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product and Services
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain NGS-Based RNA-Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product and Services
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific NGS-Based RNA-Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product and Services
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China NGS-Based RNA-Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product and Services
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India NGS-Based RNA-Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product and Services
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan NGS-Based RNA-Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product and Services
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea NGS-Based RNA-Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product and Services
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia NGS-Based RNA-Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product and Services
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America NGS-Based RNA-Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product and Services
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil NGS-Based RNA-Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product and Services
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina NGS-Based RNA-Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product and Services
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia NGS-Based RNA-Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product and Services
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa NGS-Based RNA-Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product and Services
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa NGS-Based RNA-Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product and Services
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia NGS-Based RNA-Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product and Services
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE NGS-Based RNA-Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product and Services
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Illumina Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Thermo Fischer Scientific Inc.
  • 14.3. Oxford Nanopore Technologies plc
  • 14.4. Agilent Technologies, Inc.
  • 14.5. PerkinElmer Inc
  • 14.6. QIAGEN N.V
  • 14.7. Eurofins Scientific SE
  • 14.8. F. Hoffmann-La Roche Ltd
  • 14.9. Takara Bio Inc.
  • 14.10.Azenta Life Sciences

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제